Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
Hematol Oncol. 2023 Jun;41(S1):107-111. doi: 10.1002/hon.3154.
Bispecific antibodies have been successfully introduced into the management of relapsed or refractory B-cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B-cell lymphomas, and recent phase 2 studies confirm the favourable safety and show frequent and durable complete responses even in heavily pre-treated and high-risk patients. This paper discusses the future potential role of these new agents as single agents and in combinations, and their position in the current and future treatment landscape, also in relation to chimeric antigen receptor T-cell therapy.
双特异性抗体已成功应用于复发或难治性 B 细胞淋巴瘤（包括弥漫性大 B 细胞淋巴瘤）的治疗。不同 CD3/CD20 双特异性抗体的 1 期研究显示出在多种 B 细胞淋巴瘤中具有可管理的安全性特征和有前途的疗效，最近的 2 期研究证实了其良好的安全性，并显示出频繁和持久的完全缓解，即使在经过大量预处理和高危患者中也是如此。本文讨论了这些新药物作为单一药物和联合用药的未来潜在作用，以及它们在当前和未来治疗格局中的地位，也涉及嵌合抗原受体 T 细胞疗法。
